Published reports provide evidence that the antiviral activity of products against human coronavirus (HCoV) 229E, severe acute respiratory syndrome coronavirus (SARS‐CoV), Middle East respiratory syndrome coronavirus (MERS‐CoV), or other viruses may not be generalized to the antiviral activity against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2).

The recent article by Meyers et al.¹ suffers from several interpretation issues that are not supported by the results and thereby it has the potential to mislead readers regarding health claims related to the current SARS‐CoV‐2 pandemic. The aforementioned article already received some criticism from the scientific community and mainstream print media.² We provide additional observations on this article and on research pertaining to use of oral care products in reducing SARS‐CoV‐2 viral load.

已发表的报告提供的证据表明，产品针对人类冠状病毒 (HCoV) 229E、严重急性呼吸综合征冠状病毒 (SARS-CoV)、中东呼吸综合征冠状病毒 (MERS-CoV) 或其他病毒的抗病毒活性可能无法推广到抗病毒药物对抗严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 的活性。

迈耶斯等人最近发表的文章。¹存在一些不受结果支持的解释问题，因此它有可能在与当前 SARS-CoV-2 大流行相关的健康声明方面误导读者。上述文章已经受到科学界和主流印刷媒体的一些批评。²我们对本文以及有关使用口腔护理产品减少 SARS-CoV-2 病毒载量的研究提供了额外的观察结果。